Yisheng Weina Secures Tens of Millions in Series A Funding to Build Advanced Ultrasound Core Technology R&D Platform

VCBeat has learned that,Wuxi Yisheng Weina Medical Technology Co., Ltd. (hereinafter referred to as “Yisheng Weina”)Announced the successful completion of a Series A financing round worth tens of millions of yuan. Investors includeQiao Jing CapitalandWuxi Venture Capitaland other investment institutions.

With the completion of this funding round, Wuxi Yisheng Weina Medical Technology Co., Ltd. has officially entered a new phase of development. The proceeds will be primarily allocated to rapidly expanding the R&D team, advancing product development, accelerating the operation of production facilities and commercialization efforts, achieving mass production of multiple products, continuously enhancing delivery capabilities, and meeting the rapidly growing demands of industry customers.

Yisheng Weina, established in 2021, is a platform-based innovative medical technology company specializing in the design, R&D, and manufacturing of ultrasonic transducers, with both strong scientific research capabilities and commercialization expertise. The company firmly believes that innovation drives transformation and is committed to leveraging intelligent technological innovations to break through traditional surgical methods.

The core team members of Yisheng Weina hail from the University of Science and Technology of China, Harbin Institute of Technology, Tongji University, Nanjing University, and Zhejiang University, and possess professional experience at renowned medical device companies such as GE and Philips. The company collaborates with multiple prestigious universities in China to strengthen industry-academia-research partnerships and technical exchanges, thereby ensuring sustained technological innovation.

The company has established mature solutions across its ultrasound imaging series (10F miniature interventional imaging probes, 8F miniature interventional imaging probes, and conventional external imaging probes), ultrasound therapy series (high-intensity focused ultrasound ablation and ultrasonic scalpel transducers), and ultrasound aesthetics and rehabilitation series.

Leveraging its independently developed technology platform, Yisheng Weina has completed the R&D and small-batch trial production of domestically leading 6F miniature interventional probes (phased array) and 60MHz miniature interventional probes (single-element).

In recent years, as interventional ultrasound products (ICE, IVUS) have pioneered market entry in the diagnosis and treatment of cardiovascular diseases, their application potential has expanded significantly into fields such as atrial fibrillation, structural heart disease, coronary intervention, urology, and gastroenterology.

Regarding the acquisition of this round of financing,Cheng Peifeng, Founder and Chairman of Yisheng Weinastated: “We remain dedicated to technological innovation in ultrasound-guided interventional imaging and ultrasound energy platforms, aiming to achieve a breakthrough in extending ultrasound from diagnosis to therapy, thereby providing clinicians with practical tools in the field of minimally invasive interventions.”